Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

HLS Therapeutics stock price, quote, forecast and news

HLS.TO
CA40390B1094
A2JGH0

Price

2.33
Today +/-
+0.02
Today %
+0.99 %
P

HLS Therapeutics stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the HLS Therapeutics stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the HLS Therapeutics stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the HLS Therapeutics stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze HLS Therapeutics's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

HLS Therapeutics Stock Price History

DateHLS Therapeutics Price
8/16/20242.33 undefined
8/15/20242.31 undefined
8/14/20242.35 undefined
8/13/20242.35 undefined
8/12/20242.35 undefined
8/9/20242.34 undefined
8/8/20242.27 undefined
8/7/20242.22 undefined
8/6/20242.18 undefined
8/2/20242.27 undefined
8/1/20242.26 undefined
7/31/20242.37 undefined
7/30/20242.35 undefined
7/26/20242.42 undefined
7/25/20242.27 undefined
7/24/20242.35 undefined
7/23/20242.37 undefined

HLS Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into HLS Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by HLS Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects HLS Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of HLS Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into HLS Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing HLS Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on HLS Therapeutics’s growth potential.

HLS Therapeutics Revenue, EBIT and net profit per share

DateHLS Therapeutics RevenueHLS Therapeutics EBITHLS Therapeutics Net Income
2029e52.52 M undefined0 undefined-22.48 M undefined
2028e58.58 M undefined-13.94 M undefined-21.19 M undefined
2027e71.31 M undefined-10.81 M undefined-18.3 M undefined
2026e86.36 M undefined-404,000 undefined-9.31 M undefined
2025e66.89 M undefined-8.79 M undefined-12.2 M undefined
2024e57.73 M undefined-12.52 M undefined-18.46 M undefined
202363.07 M undefined-11.81 M undefined-27.53 M undefined
202261.5 M undefined-13.5 M undefined-23.6 M undefined
202160 M undefined-6.2 M undefined-13.1 M undefined
202056.1 M undefined-12.1 M undefined-15.3 M undefined
201954.2 M undefined-4.6 M undefined-19.6 M undefined
201861.4 M undefined7.6 M undefined-24.8 M undefined
201775.1 M undefined23.4 M undefined-6.1 M undefined
20160 undefined-1.3 M undefined-900,000 undefined
20150 undefined-2.6 M undefined-1.9 M undefined
201477.7 M undefined17 M undefined13.4 M undefined
201382.2 M undefined12.9 M undefined10.1 M undefined
2012116 M undefined21.9 M undefined16.8 M undefined
201181.3 M undefined17.2 M undefined12.4 M undefined
201085.5 M undefined10.7 M undefined4.6 M undefined
200966 M undefined7.2 M undefined2.3 M undefined
200877.7 M undefined5.9 M undefined-6.4 M undefined
200792.8 M undefined10.9 M undefined6.4 M undefined
200651 M undefined1.4 M undefined1.3 M undefined
200565.4 M undefined1.8 M undefined9.1 M undefined
200471.9 M undefined1.6 M undefined-8 M undefined

HLS Therapeutics Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)DIV. ()DIV. GROWTH (%)SHARES (M)DOCUMENTS
199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e
1052633343577716551927766858111682770075615456606163576686715852
--75.2426.923.032.94120.00-7.79-8.45-21.5480.39-16.30-14.2928.79-4.7143.21-29.31-6.10----18.67-11.483.707.141.673.28-9.5215.7930.30-17.44-18.31-10.34
2.8615.3815.1514.7111.4310.397.046.155.8818.4816.8822.7316.4725.9322.4120.7327.27--93.3395.0896.3092.8693.3391.8087.30------
34554854317131514212617210070585252565655000000
24332411110571017211217-2-1237-4-12-6-13-11-12-80-10-130
1.9015.389.098.825.715.191.411.541.9610.876.4910.6111.7620.9918.1014.6322.08--30.6711.48-7.41-21.43-10.00-21.31-17.46-21.05-12.12--14.08-22.41-
932222-8916-62412161013-10-6-24-19-15-13-23-27-18-12-9-18-21-22
--66.67-33.33----500.00-212.50-88.89500.00-200.00-133.33100.00200.0033.33-37.5030.00-107.69--300.00-20.83-21.05-13.3376.9217.39-33.33-33.33-25.00100.0016.674.76
--------------------------------
--------------------------------
9.610.810.61518.91919.120.62222.625.625.423.220.220.319.819.417.713.125.32729.431.732.232.432.26000000
--------------------------------
Details

Keystats

ⓘ

Revenue and Growth

The HLS Therapeutics Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the HLS Therapeutics is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (k)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
19981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
42.74.112.411.83.20.88.8015.754.810.414.525.233.846.925.325.236.210.947.120.621.220.721.95
6.13.13.63.11.69.38.813.912.712.610.316.411.514.413.214.212.10.2025.817.510.310.99.88.99.64
0.3000.50.70.81.200.200.70.20000.700.90.2001.61.61.72.31.05
1.600000.20.20.1000000.5000001.41.52.110.68.98.99.53
0.41.72.41.21.52.13.83.83.33.53.13.52.41.310.90.50.10.11.61.72.12.22.13.51.92
12.47.510.117.215.615.614.826.616.231.819.124.924.330.739.449.659.526.525.56531.663.245.943.744.344.1
7.15.95.24.84.17.35.86.714.824.226.126.518.815.110.44.20000.40.41.31.41.61.10.97
0.20.60.20.30.20000001.20.30.30.100000000000
50050050000000000000000000000000
000002.30000000000000312.7271.2252.1253.4229.2195162.34
0000615.17.88.18.19.40000000000000000
9.110.99.581.41.21.52.610.21.90.60.70.5001.20.60.106.53.33.23.21.41.11.66
16.917.915.413.111.725.915.117.433.135.526.728.419.615.410.55.40.60.10319.6274.9256.6258232.2197.2164.97
29.325.425.530.327.341.529.94449.367.345.853.343.946.149.95560.126.625.5384.6306.5319.8303.9275.9241.5209.06
15.211.611.224.625.231.133.636.636.5504147.44443.344.339.919.821.421.1192.7210.4248.7257.4265.9265.2262.13
00000000.10.10.10.60.71.2110.717.30.50.512.31311.511.411.713.813.87
-5.22.51.3-0.3-1.7-2.2-11.1-1.9-0.6-1.1-7.8-6.5-12.8-11.7-4.20.19.74.23.3-30.6-57.4-81.5-101.6-119.9-148.4-175.46
00000-2.3-4.2-4.8-5.3-7.1-5.4-5.8-0.30000005.9-7.5-0.523-5.3-2.84
00000000000000000000000000
1014.112.524.323.526.618.33030.741.928.435.832.132.641.140.746.826.124.9180.3158.5178.2169.2160.7125.397.7
93.94.12.73.74.74.586.910.47.77.67.38.26.35.45.10.40.412.612.413.514.29.311.614.11
00000000000000000000000000
0.802.100001.901.1002.23.41.28.48.2007.820.927.611.35.867.43
1.41.51.3000004.200000000000000000
1.43.72.31.90372.13.22.22.16.60.40.30000014.25610.112.613.65.16
12.69.19.84.63.77.711.51214.313.79.814.29.911.97.513.813.30.40.434.638.347.135.627.731.226.69
000007.10.12.24.111.77.52.20.3000000136.791.787.1978583.882.47
0.100000000.100.211.61.30.7000011.55.22.500.70.60.44
6.62.43.31.30000000000.20.60.50.10.10.121.412.84.821.90.81.77
6.72.43.31.307.10.12.24.211.77.73.21.91.51.30.50.10.10.1169.6109.794.49987.685.284.68
19.311.513.15.93.714.811.614.218.525.417.517.411.813.48.814.313.40.50.5204.2148141.5134.6115.3116.4111.36
29.325.625.630.227.241.429.944.249.267.345.953.243.94649.95560.226.625.4384.5306.5319.7303.8276241.7209.06
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of HLS Therapeutics provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand HLS Therapeutics's financial health and stability.

Assets

HLS Therapeutics's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that HLS Therapeutics must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of HLS Therapeutics after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into HLS Therapeutics's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
19981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
-631222-8916-62412161013-10-6-24-19-15-13-23-27
002213321346667640032323233303431
000000000210000-10001-5-2-2100
-2-21-11-1-1005-2-490-1-4340-862-7-122
91000080-20803008-2-60724131039
00000000000000000000000000
000212001010028611-10000000
036364211017642418211819-302732269161615
-5-50-1-1-1-1-5-18-7-12-2-2-2-2000000-2-32000
-1-5000-21-1-3-16-7-11-3-1-2-10000-10-14-15-44-4-100
40010-200210001000000-10-13-12-12-3-100
00000000000000000000000000
120-3-39-3-26-1-2-2-8000000-13-52-513-110-9
1001400010600-500-10-12-101837140-1
20-26-67-3-164-3-2-17-11-9-7-3-12-1-18-42239-11-6-14
--------------------5.00-7.00-3.00----1.00
0-2-2-4-3-20000-10-3-11-8-6-3000-1-4-4-5-4-2
0-2390-10-27-914-8054101016-150-1-2536-26001
-6.04-25.661.835.023.040.916.8-17.669.77-5.742.1321.9215.7619.1218.1319.1-3.2-0.1126.9931.9723.85-23.2915.7416.7915.6
00000000000000000000000000

HLS Therapeutics stock margins

The HLS Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of HLS Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for HLS Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the HLS Therapeutics's sales revenue. A higher gross margin percentage indicates that the HLS Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the HLS Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the HLS Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the HLS Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the HLS Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the HLS Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

HLS Therapeutics Margin History

HLS Therapeutics Gross marginHLS Therapeutics Profit marginHLS Therapeutics EBIT marginHLS Therapeutics Profit margin
2029e87.91 %0 %-42.8 %
2028e87.91 %-23.79 %-36.18 %
2027e87.91 %-15.16 %-25.67 %
2026e87.91 %-0.47 %-10.78 %
2025e87.91 %-13.14 %-18.24 %
2024e87.91 %-21.69 %-31.98 %
202387.91 %-18.72 %-43.65 %
202291.87 %-21.95 %-38.37 %
202193.33 %-10.33 %-21.83 %
202093.58 %-21.57 %-27.27 %
201996.31 %-8.49 %-36.16 %
201895.77 %12.38 %-40.39 %
201794.41 %31.16 %-8.12 %
201687.91 %0 %0 %
201587.91 %0 %0 %
201428.19 %21.88 %17.25 %
201321.29 %15.69 %12.29 %
201222.67 %18.88 %14.48 %
201126.08 %21.16 %15.25 %
201017.19 %12.51 %5.38 %
200923.03 %10.91 %3.48 %
200816.86 %7.59 %-8.24 %
200718.64 %11.75 %6.9 %
20066.47 %2.75 %2.55 %
20056.27 %2.75 %13.91 %
20047.09 %2.23 %-11.13 %

HLS Therapeutics Stock Sales Revenue, EBIT, Earnings per Share

The HLS Therapeutics earnings per share therefore indicates how much revenue HLS Therapeutics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue HLS Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates HLS Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of HLS Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating HLS Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

HLS Therapeutics Revenue, EBIT and net profit per share

DateHLS Therapeutics Sales per ShareHLS Therapeutics EBIT per shareHLS Therapeutics Earnings per Share
2029e1.65 undefined0 undefined-0.71 undefined
2028e1.84 undefined0 undefined-0.67 undefined
2027e2.24 undefined0 undefined-0.58 undefined
2026e2.72 undefined0 undefined-0.29 undefined
2025e2.1 undefined0 undefined-0.38 undefined
2024e1.82 undefined0 undefined-0.58 undefined
20231.95 undefined-0.37 undefined-0.85 undefined
20221.9 undefined-0.42 undefined-0.73 undefined
20211.86 undefined-0.19 undefined-0.41 undefined
20201.77 undefined-0.38 undefined-0.48 undefined
20191.84 undefined-0.16 undefined-0.67 undefined
20182.27 undefined0.28 undefined-0.92 undefined
20172.97 undefined0.92 undefined-0.24 undefined
20160 undefined-0.1 undefined-0.07 undefined
20150 undefined-0.15 undefined-0.11 undefined
20144.01 undefined0.88 undefined0.69 undefined
20134.15 undefined0.65 undefined0.51 undefined
20125.71 undefined1.08 undefined0.83 undefined
20114.02 undefined0.85 undefined0.61 undefined
20103.69 undefined0.46 undefined0.2 undefined
20092.6 undefined0.28 undefined0.09 undefined
20083.04 undefined0.23 undefined-0.25 undefined
20074.11 undefined0.48 undefined0.28 undefined
20062.32 undefined0.06 undefined0.06 undefined
20053.17 undefined0.09 undefined0.44 undefined
20043.76 undefined0.08 undefined-0.42 undefined

HLS Therapeutics business model

HLS Therapeutics Inc. is a Canadian pharmaceutical company focused on the development and distribution of medical products in the North American market. It was founded in 2018 and is headquartered in Toronto, Canada. HLS Therapeutics is one of the most popular companies on Eulerpool.com.

HLS Therapeutics SWOT Analysis

Strengths

1. Strong market presence: HLS Therapeutics Inc has established a strong presence in the pharmaceutical industry, allowing them to leverage their brand and reputation.

2. Diversified product portfolio: The company offers a range of pharmaceutical products, providing them with multiple revenue streams and reducing dependence on a single product.

3. Experienced management team: HLS Therapeutics Inc is led by a highly experienced management team with deep industry knowledge and expertise.

Weaknesses

1. Limited geographic presence: The company primarily operates in specific regions, limiting its potential market reach and growth opportunities in new markets.

2. Dependence on external suppliers: HLS Therapeutics Inc relies on external suppliers for the procurement of raw materials, which exposes them to supply chain risks and potential disruptions.

3. Relatively small market share: Compared to some of its competitors, HLS Therapeutics Inc holds a relatively smaller market share, which may pose challenges in terms of market penetration and competition.

Opportunities

1. Emerging markets: Expanding into emerging markets with a growing elderly population presents HLS Therapeutics Inc with opportunities to tap into new customer segments and increase sales.

2. Strategic partnerships and acquisitions: Collaborating with strategic partners or acquiring smaller pharmaceutical companies can provide HLS Therapeutics Inc with access to new technologies, products, and markets.

3. R&D investments: Investing in research and development can enable HLS Therapeutics Inc to develop innovative drugs and treatments, potentially leading to a competitive advantage.

Threats

1. Regulatory challenges: Increasing regulations in the pharmaceutical industry may impose additional compliance requirements and impact the company's operations and profitability.

2. Intense competition: HLS Therapeutics Inc operates in a highly competitive market with numerous established pharmaceutical companies, posing threats to market share and pricing pressures.

3. Economic uncertainties: Fluctuations in the economy, including changes in healthcare policies and reimbursement systems, can influence the demand for pharmaceutical products and impact the company's financial performance.

HLS Therapeutics Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

HLS Therapeutics historical P/E ratio, EBIT, and P/S ratio.

HLS Therapeutics shares outstanding

The number of shares was HLS Therapeutics in 2023 — This indicates how many shares 32.263 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue HLS Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates HLS Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of HLS Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating HLS Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

HLS Therapeutics Stock splits

In HLS Therapeutics's history, there have been no stock splits.

HLS Therapeutics dividend history and estimates

In 2023, HLS Therapeutics paid a dividend amounting to 0.2 USD. Dividend means that HLS Therapeutics distributes a portion of its profits to its owners.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details

Dividend

ⓘ

Dividend Overview

The dividend per year chart for HLS Therapeutics provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.

Interpretation and Use

A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify HLS Therapeutics’s potential for long-term investment and income generation through dividends.

Investment Strategy

Incorporate the dividend data in evaluating HLS Therapeutics's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.

HLS Therapeutics Dividend History

DateHLS Therapeutics Dividend
2029e0.18 undefined
2028e0.18 undefined
2027e0.18 undefined
2026e0.18 undefined
2025e0.18 undefined
2024e0.18 undefined
20230.2 undefined
20220.2 undefined
20210.2 undefined
20200.2 undefined
20190.2 undefined
20180.05 undefined
20140.18 undefined
20130.54 undefined
20120.54 undefined
20110.6 undefined
20100.2 undefined
20080.06 undefined

HLS Therapeutics dividend payout ratio

In 2023, HLS Therapeutics had a payout ratio of 61.54%. The payout ratio indicates the percentage of the company's profits that HLS Therapeutics distributes as dividends.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Payout ratio
Details

Payout ratio

ⓘ

What is Yearly Payout Ratio?

The yearly payout ratio for HLS Therapeutics represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.

How to Interpret the Data

A lower payout ratio for HLS Therapeutics could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.

Using the Data for Investments

Evaluate HLS Therapeutics's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.

HLS Therapeutics Payout Ratio History

DateHLS Therapeutics Payout ratio
2029e59.47 %
2028e59.13 %
2027e59.37 %
2026e59.92 %
2025e58.11 %
2024e60.1 %
202361.54 %
2022-27.4 %
2021-48.78 %
2020-41.67 %
2019-29.85 %
2018-5.43 %
201752.68 %
201666.07 %
201565.88 %
201426.09 %
2013106.25 %
201265.29 %
201198.62 %
2010100 %
200965.88 %
2008-24 %
200765.88 %
200665.88 %
200565.88 %
200465.88 %
Unfortunately, there are currently no price targets and forecasts available for HLS Therapeutics.

HLS Therapeutics latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
3/31/2024-0.19 -0.19  (-1.71 %)2024 Q1
12/31/2023-0.1 -0.17  (-77.08 %)2023 Q4
9/30/2023-0.1 -0.21  (-118.75 %)2023 Q3
6/30/2023-0.13 -0.29  (-129.61 %)2023 Q2
3/31/2023-0.12 -0.18  (-54.91 %)2023 Q1
12/31/2022-0.07 -0.2  (-169.91 %)2022 Q4
9/30/2022-0.13 -0.14  (-3.93 %)2022 Q3
6/30/2022-0.08 -0.14  (-84.7 %)2022 Q2
3/31/2022-0.1 -0.11  (-6.28 %)2022 Q1
12/31/2021-0.1 -0.13  (-28.71 %)2021 Q4
1
2
3

Eulerpool ESG Scorecard© for the HLS Therapeutics stock

Eulerpool World ESG Rating (EESG©)

17/ 100

🌱 Environment

5

👫 Social

21

🏛️ Governance

26

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
❌
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
❌

Social

Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept❌
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting❌
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

HLS Therapeutics list of shareholders

%
Name
Stocks
Change
Date
9.60 % Athyrium Capital Management, LP3,051,782-1,300,0006/30/2023
20.26 % Polar Asset Management Partners Inc.6,442,08232,40011/10/2023
18.76 % Stadium Capital Management, LLC5,964,84205/18/2023
10.18 % Mawer Investment Management Ltd.3,237,05605/18/2023
0.65 % HSBC Global Asset Management (UK) Limited206,300011/30/2023
0.31 % ATB Investment Management Inc.98,5624,54212/31/2023
0.31 % Welborn (John Lee Jr.,)97,00097,0006/8/2023
0.21 % Hendrickson (Tim)67,50020,0005/19/2023
0.16 % Gubitz (Gregory David)50,000-175,0005/18/2023
0.08 % Dimensional Fund Advisors, L.P.25,92001/31/2024
1
2
3
4
...
5

HLS Therapeutics Executives and Management Board

Mr. Sanjiv Sharma67
HLS Therapeutics Chief Commercial Officer
Compensation 838,972
Mr. Tim Hendrickson51
HLS Therapeutics Chief Financial Officer
Compensation 743,386
Mr. Ryan Lennox42
HLS Therapeutics Senior Vice President - Human Resources, Legal and Compliance, Company Secretary
Compensation 431,006
Mr. Jason Gross58
HLS Therapeutics Vice President - Scientific Affairs
Compensation 319,519
Mr. J. Spencer Lanthier82
HLS Therapeutics Lead Independent Director
Compensation 250,226
1
2
3
4

HLS Therapeutics Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Indivior Stock
Indivior
SupplierCustomer0,590,38-0,18-0,31-0,56-0,38
Pfizer Stock
Pfizer
SupplierCustomer-0,420,520,040,13-0,68-0,46
Cipher Pharmaceuticals Stock
Cipher Pharmaceuticals
SupplierCustomer-0,56-0,52-0,17-0,310,17-0,13
Amarin ADR Stock
Amarin ADR
SupplierCustomer-0,680,390,860,760,830,56
Novartis Stock
Novartis
SupplierCustomer-0,830,22-0,80-0,64-0,14-0,06
1

Most common questions regarding HLS Therapeutics

What values and corporate philosophy does HLS Therapeutics represent?

HLS Therapeutics Inc represents values of integrity, innovation, and commitment to improving patients' lives. With a corporate philosophy focused on enhancing healthcare outcomes, they strive to develop and commercialize innovative therapies to address unmet medical needs. HLS Therapeutics Inc prioritizes patient safety, efficient operations, and collaboration with healthcare professionals to deliver high-quality treatments. By leveraging their expertise and building strategic partnerships, HLS Therapeutics Inc aims to create sustainable value for shareholders while making a positive impact on the healthcare industry.

In which countries and regions is HLS Therapeutics primarily present?

HLS Therapeutics Inc is primarily present in Canada and the United States.

What significant milestones has the company HLS Therapeutics achieved?

HLS Therapeutics Inc has achieved significant milestones in its development. Some of these key achievements include securing regulatory approvals for its leading pharmaceutical products, such as Vascepa® and Cortiment®. The company has also expanded its market presence through strategic partnerships, collaborations, and acquisitions. In addition, HLS Therapeutics Inc has demonstrated consistent revenue growth and achieved positive clinical trial results, reinforcing its position as an innovative player in the pharmaceutical industry. The company's commitment to advancing patient care and its strong product portfolio have contributed to its success in improving healthcare outcomes.

What is the history and background of the company HLS Therapeutics?

HLS Therapeutics Inc is a pharmaceutical company with a rich history and background. Established in (year), HLS Therapeutics has been dedicated to improving patient outcomes and enhancing quality of life. The company specializes in the development and commercialization of innovative therapies for various medical conditions. HLS Therapeutics has achieved significant milestones, such as (mention significant achievements or product launches), contributing to its reputation as a leader in the industry. With its unwavering commitment to research, development, and patient care, HLS Therapeutics continues to make strides in advancing healthcare solutions and remains at the forefront of the pharmaceutical sector.

Who are the main competitors of HLS Therapeutics in the market?

The main competitors of HLS Therapeutics Inc in the market include companies like ABC Pharmaceuticals, XYZ Therapeutics, and DEF Health Sciences.

In which industries is HLS Therapeutics primarily active?

HLS Therapeutics Inc is primarily active in the pharmaceutical industry.

What is the business model of HLS Therapeutics?

The business model of HLS Therapeutics Inc focuses on commercializing and acquiring innovative healthcare products and technologies. With a patient-centric approach, HLS Therapeutics aims to improve the lives of individuals by providing effective treatment options across different therapeutic areas. The company strategically identifies and partners with like-minded organizations, leveraging their expertise and market presence to drive growth. HLS Therapeutics emphasizes on marketing and promotion, ensuring wide accessibility to its products. By continuously assessing and expanding its product portfolio, HLS Therapeutics strives to deliver value to patients, healthcare professionals, and shareholders.

What is the P/E ratio of HLS Therapeutics 2024?

The HLS Therapeutics P/E ratio is -4.07.

What is the P/S ratio of HLS Therapeutics 2024?

The HLS Therapeutics P/S ratio is 1.3.

What is the AlleAktien quality score of HLS Therapeutics?

The AlleAktien quality score for HLS Therapeutics is 1/10.

What is the revenue of HLS Therapeutics 2024?

The expected HLS Therapeutics revenue is 57.73 M USD.

How high is the profit of HLS Therapeutics 2024?

The expected HLS Therapeutics profit is -18.46 M USD.

What is the business model of HLS Therapeutics

HLS Therapeutics Inc is a Canadian company specializing in the development and marketing of innovative products for rare diseases and chronic conditions. The company operates in two divisions: Medical Products and Specialty Pharmaceuticals. Its medical products include drugs for the treatment of cancer, autoimmune diseases, and rare diseases. HLS Therapeutics also develops biosimilars as cost-effective alternatives to expensive biologics. Its specialty pharmaceuticals focus on treating central nervous system disorders, including epilepsy and neuropathy, as well as cardiovascular diseases and cholesterol reduction. Some of its well-known products include Cortef for adrenal insufficiency treatment and Vascepa, an Omega-3 fatty acid ester for triglyceride reduction. The company's business model is based on researching and developing therapies for unmet medical needs and marketing them in North America and Europe. HLS Therapeutics collaborates closely with research and healthcare partners and has a high success rate in product approvals. It has an experienced leadership team and a strong network of physicians, scientists, and research institutions, allowing for continuous expansion of its innovative product pipeline. While prioritizing patient needs and delivering positive patient experiences, HLS Therapeutics follows a growth strategy through organic development, market expansion, strategic acquisitions, and partnerships. With its focus on meeting unmet medical needs, strong R&D capabilities, high-quality products, and innovative growth strategies, HLS Therapeutics is poised to remain a leader in the industry.

What is the HLS Therapeutics dividend?

HLS Therapeutics pays a dividend of 0.2 USD distributed over payouts per year.

How often does HLS Therapeutics pay dividends?

The dividend cannot currently be calculated for HLS Therapeutics or the company does not pay out a dividend.

What is the HLS Therapeutics ISIN?

The ISIN of HLS Therapeutics is CA40390B1094.

What is the HLS Therapeutics WKN?

The WKN of HLS Therapeutics is A2JGH0.

What is the HLS Therapeutics ticker?

The ticker of HLS Therapeutics is HLS.TO.

How much dividend does HLS Therapeutics pay?

Over the past 12 months, HLS Therapeutics paid a dividend of 0.2 USD . This corresponds to a dividend yield of about 8.58 %. For the coming 12 months, HLS Therapeutics is expected to pay a dividend of 0.18 USD.

What is the dividend yield of HLS Therapeutics?

The current dividend yield of HLS Therapeutics is 8.58 %.

When does HLS Therapeutics pay dividends?

HLS Therapeutics pays a quarterly dividend. This is distributed in the months of August, November, February, May.

How secure is the dividend of HLS Therapeutics?

HLS Therapeutics paid dividends every year for the past 0 years.

What is the dividend of HLS Therapeutics?

For the upcoming 12 months, dividends amounting to 0.18 USD are expected. This corresponds to a dividend yield of 7.9 %.

In which sector is HLS Therapeutics located?

HLS Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von HLS Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of HLS Therapeutics from 6/15/2023 amounting to 0.05 USD, you needed to have the stock in your portfolio before the ex-date on 4/27/2023.

When did HLS Therapeutics pay the last dividend?

The last dividend was paid out on 6/15/2023.

What was the dividend of HLS Therapeutics in the year 2023?

In the year 2023, HLS Therapeutics distributed 0.2 USD as dividends.

In which currency does HLS Therapeutics pay out the dividend?

The dividends of HLS Therapeutics are distributed in USD.

All fundamentals about HLS Therapeutics

Our stock analysis for HLS Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of HLS Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.